At the same time, CAP1 was efficient in inhibiting the seeding capacity of tau polymorphs isolated from AD patient brain samples, thus indicating the strength of this comprehensive approach in significantly improving the selective affinity of inhibitor designs that can target multiple amyloid polymorphs and suggesting that this is a promising methodology for the development of therapeutics in amyloidosis diseases. This evidence concerns the gene CAP1 and Alzheimer disease.